1. Home
  2. MESO
  3. MESO News

Latest Mesoblast Limited (MESO) News on December 26, 2024

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MESO

Zacks

7 days ago

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
MESO

Pharmaceutical Technology

7 days ago

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
MESO

Benzinga

7 days ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

MESO

MT Newswires

7 days ago

Mesoblast Says Ryoncil Receives FDA Approval for Acute Graft Versus Host Disease; Shares Rise Pre-Bell

Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval
MESO

Investor's Business Daily

8 days ago

Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval

Mesoblast to be Added to Nasdaq Biotechnology Index
MESO

GlobeNewswire

8 days ago

Mesoblast to be Added to Nasdaq Biotechnology Index

DREAM-HF trial sheds positive light on Revascor for ischemic HF
MESO

Clinical Trials Arena

13 days ago

DREAM-HF trial sheds positive light on Revascor for ischemic HF

3 ASX Growth Companies With Insider Ownership Up To 38%
MESO

Simply Wall St.

17 days ago

3 ASX Growth Companies With Insider Ownership Up To 38%

Mesoblast’s Revascor Therapy Shows Promise in Heart Failure
MESO

TipRanks

21 days ago

Mesoblast’s Revascor Therapy Shows Promise in Heart Failure

MESO

MT Newswires

21 days ago

Mesoblast Says FDA Granted Regenerative Medicine Advanced Therapy Designation for Revascor

Exploring High Growth Tech Stocks in Australia December 2024
MESO

Simply Wall St.

22 days ago

Exploring High Growth Tech Stocks in Australia December 2024

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
MESO

GlobeNewswire

22 days ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

MESO

MT Newswires

23 days ago

Mesoblast Says Revascor Improved Survival in Ischemic Heart Failure Patients

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
MESO

GlobeNewswire

24 days ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders
MESO

Simply Wall St.

a month ago

Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders

Mesoblast Issues 2 Million Warrants for Strategic Flexibility
MESO

TipRanks

a month ago

Mesoblast Issues 2 Million Warrants for Strategic Flexibility

ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth
MESO

Simply Wall St.

2 months ago

ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth

Three High Growth Tech Stocks in Australia
MESO

Simply Wall St.

2 months ago

Three High Growth Tech Stocks in Australia

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
MESO

GlobeNewswire

2 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

When Will Mesoblast Limited (ASX:MSB) Become Profitable?
MESO

Simply Wall St.

2 months ago

When Will Mesoblast Limited (ASX:MSB) Become Profitable?

Mesoblast Advances Cellular Medicines Amid FDA Hopes
MESO

TipRanks

2 months ago

Mesoblast Advances Cellular Medicines Amid FDA Hopes

ASX Growth Companies With High Insider Ownership In October 2024
MESO

Simply Wall St.

3 months ago

ASX Growth Companies With High Insider Ownership In October 2024

3 ASX Growth Companies With Insider Ownership Up To 37%
MESO

Simply Wall St.

3 months ago

3 ASX Growth Companies With Insider Ownership Up To 37%

3 ASX Growth Stocks With Insider Ownership Up To 36%
MESO

Simply Wall St.

3 months ago

3 ASX Growth Stocks With Insider Ownership Up To 36%

Exploring High Growth Tech Stocks In Australia
MESO

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks In Australia

3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth
MESO

Simply Wall St.

3 months ago

3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth

ASX Growth Companies With High Insider Ownership For October 2024
MESO

Simply Wall St.

3 months ago

ASX Growth Companies With High Insider Ownership For October 2024

3 High Growth Tech Stocks in Australia to Watch
MESO

Simply Wall St.

3 months ago

3 High Growth Tech Stocks in Australia to Watch

3 ASX Growth Stocks With High Insider Ownership
MESO

Simply Wall St.

3 months ago

3 ASX Growth Stocks With High Insider Ownership

3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth
MESO

Simply Wall St.

3 months ago

3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth

Exploring Three High Growth Tech Stocks In Australia
MESO

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In Australia

3 ASX Growth Companies Insiders Are Investing In
MESO

Simply Wall St.

3 months ago

3 ASX Growth Companies Insiders Are Investing In

ASX Growth Companies With High Insider Ownership In October 2024
MESO

Simply Wall St.

3 months ago

ASX Growth Companies With High Insider Ownership In October 2024

ASX Growth Companies With High Insider Ownership October 2024
MESO

Simply Wall St.

3 months ago

ASX Growth Companies With High Insider Ownership October 2024

3 High Growth ASX Stocks With Significant Insider Ownership
MESO

Simply Wall St.

3 months ago

3 High Growth ASX Stocks With Significant Insider Ownership

Top High Growth Tech Stocks To Watch In Australia October 2024
MESO

Simply Wall St.

3 months ago

Top High Growth Tech Stocks To Watch In Australia October 2024

MESO

MT Newswires

3 months ago

Mesoblast to Issue up to $50 Million of Convertible Notes for Product Launch of Ryoncil on FDA Approval

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
MESO

GlobeNewswire

3 months ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies
MESO

Insider Monkey

3 months ago

Mesoblast (MESO): Biotechnology Innovator Nearing Critical Milestones for Life-Changing Therapies

3 ASX Growth Companies With High Insider Ownership To Watch
MESO

Simply Wall St.

3 months ago

3 ASX Growth Companies With High Insider Ownership To Watch

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?
MESO

Insider Monkey

4 months ago

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?

Exploring 3 High Growth Tech Stocks in Australia
MESO

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks in Australia

Mesoblast Full Year 2024 Earnings: Misses Expectations
MESO

Simply Wall St.

4 months ago

Mesoblast Full Year 2024 Earnings: Misses Expectations

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
MESO

GlobeNewswire

4 months ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Mesoblast Financial Results and Corporate Update Webcast
MESO

GlobeNewswire

4 months ago

Mesoblast Financial Results and Corporate Update Webcast

Exploring 3 High Growth Tech Stocks In Australia
MESO

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In Australia

Investors in Mesoblast (ASX:MSB) have seen impressive returns of 154% over the past year
MESO

Simply Wall St.

4 months ago

Investors in Mesoblast (ASX:MSB) have seen impressive returns of 154% over the past year

Mesoblast Insiders Land Bargain With Gains Of US$58m
MESO

Simply Wall St.

5 months ago

Mesoblast Insiders Land Bargain With Gains Of US$58m

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
MESO

GlobeNewswire

5 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
MESO

Pharmaceutical Technology

5 months ago

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy

MESO

MT Newswires

5 months ago

Mesoblast Says FDA Accepted Resubmitted Biologics License Application for Ryoncil; Shares Rise Pre-Bell

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

5 months ago

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast begins subject enrolment in Phase III back pain treatment trial
MESO

Clinical Trials Arena

5 months ago

Mesoblast begins subject enrolment in Phase III back pain treatment trial

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
MESO

GlobeNewswire

5 months ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
MESO

Simply Wall St.

6 months ago

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects

Insider-Owned ASX Growth Companies To Watch In July 2024
MESO

Simply Wall St.

6 months ago

Insider-Owned ASX Growth Companies To Watch In July 2024

MESO

MT Newswires

6 months ago

Mesoblast Resubmits Ryoncil Biologics License Application

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

6 months ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
MESO

Zacks

6 months ago

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
MESO

GlobeNewswire

6 months ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

ASX Growth Companies With High Insider Ownership To Watch In June 2024
MESO

Simply Wall St.

6 months ago

ASX Growth Companies With High Insider Ownership To Watch In June 2024

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%
MESO

Simply Wall St.

6 months ago

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%

High Insider Ownership Growth Stocks On The ASX In June 2024
MESO

Simply Wall St.

6 months ago

High Insider Ownership Growth Stocks On The ASX In June 2024

Exploring Three ASX Growth Companies With Significant Insider Ownership
MESO

Simply Wall St.

6 months ago

Exploring Three ASX Growth Companies With Significant Insider Ownership

Mesoblast Corporate Presentation at Investor Conference
MESO

GlobeNewswire

7 months ago

Mesoblast Corporate Presentation at Investor Conference

ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth
MESO

Simply Wall St.

7 months ago

ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth

ASX Growth Leaders With High Insider Ownership Explored
MESO

Simply Wall St.

7 months ago

ASX Growth Leaders With High Insider Ownership Explored

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Of At Least 14%
MESO

Simply Wall St.

7 months ago

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Of At Least 14%

May 2024 Insight Into ASX Growth Companies With High Insider Ownership
MESO

Simply Wall St.

7 months ago

May 2024 Insight Into ASX Growth Companies With High Insider Ownership

ASX Growth Companies With High Insider Ownership And At Least 14% Earnings Growth
MESO

Simply Wall St.

7 months ago

ASX Growth Companies With High Insider Ownership And At Least 14% Earnings Growth

Exploring Three ASX Growth Companies With High Insider Ownership
MESO

Simply Wall St.

7 months ago

Exploring Three ASX Growth Companies With High Insider Ownership

Exploring Three ASX Growth Companies With Significant Insider Ownership
MESO

Simply Wall St.

7 months ago

Exploring Three ASX Growth Companies With Significant Insider Ownership

ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%
MESO

Simply Wall St.

7 months ago

ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%

ASX Growth Leaders With High Insider Ownership To Watch
MESO

Simply Wall St.

7 months ago

ASX Growth Leaders With High Insider Ownership To Watch

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
MESO

GlobeNewswire

8 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
MESO

Simply Wall St.

8 months ago

Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO

Zacks

9 months ago

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
MESO

Benzinga

9 months ago

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
MESO

GlobeNewswire

9 months ago

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
MESO

GlobeNewswire

9 months ago

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
MESO

GlobeNewswire

10 months ago

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
MESO

Insider Monkey

10 months ago

Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript

Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
MESO

Simply Wall St.

10 months ago

Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
MESO

GlobeNewswire

10 months ago

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Financial Results and Corporate Update Webcast
MESO

GlobeNewswire

10 months ago

Mesoblast Financial Results and Corporate Update Webcast

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
MESO

GlobeNewswire

10 months ago

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
MESO

GlobeNewswire

a year ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report
MESO

ACCESSWIRE

a year ago

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024
MESO

PR Newswire

a year ago

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

Mid Penn Bancorp Full Year 2023 Earnings: EPS Misses Expectations
MESO

Simply Wall St.

a year ago

Mid Penn Bancorp Full Year 2023 Earnings: EPS Misses Expectations

OneWater Marine (ONEW) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MESO

Zacks

a year ago

OneWater Marine (ONEW) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MESO

Associated Press Finance

a year ago

CNB: Q4 Earnings Snapshot

CNB Financial Corporation Reports Fourth Quarter and Full-Year 2023 Results
MESO

GlobeNewswire

a year ago

CNB Financial Corporation Reports Fourth Quarter and Full-Year 2023 Results

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations
MESO

PR Newswire

a year ago

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
MESO

Zacks

a year ago

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
MESO

GlobeNewswire

a year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

With 50% ownership of the shares, Quipt Home Medical Corp. (TSE:QIPT) is heavily dominated by institutional owners
MESO

Simply Wall St.

a year ago

With 50% ownership of the shares, Quipt Home Medical Corp. (TSE:QIPT) is heavily dominated by institutional owners

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Cash Distribution
MESO

Business Wire

a year ago

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Cash Distribution

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
MESO

GlobeNewswire

a year ago

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

MESO

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Share on Social Networks: